Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2018 Mar 1.
Published in final edited form as: Arterioscler Thromb Vasc Biol. 2017 Mar;37(3):387–388. doi: 10.1161/ATVBAHA.116.308842

Non-canonical Wnts at the Cusp of Fibrocalcific Signaling Processes in Human Calcific Aortic Valve Disease

Cecilia M Giachelli 1, Mei Y Speer 1
PMCID: PMC5324977  NIHMSID: NIHMS838646  PMID: 28228443

Calcific aortic valve disease (CAVD), the progressive accumulation of fibrocalcific matrices and calcified, bony nodules in aortic valves that results in aortic stenosis (AS), accounts for ~50% of cardiac valve disease.1, 2 In developed countries, CAVD is the third most common cardiovascular disease behind coronary artery disease and hypertension.3 While CAVD is often asymptomatic during the first several decades of life, notably, ~1/3 of our elderly have early valve disease as indicated by echocardiographic or radiological evidence of aortic sclerosis.2, 4, 5 By age 65, ~2% of individuals develop symptomatic AS, characterized by severe valve calcification, impaired leaflet motion and cardiac outflow, which, if untreated, leads to life threatening left ventricular dysfunction, angina, syncope, and heart failure.6, 7

CAVD risk factors include congenital malformation, age, male sex, smoking, hypercholesterolemia, hypertension, and diabetes mellitus.8 Importantly, level of aortic valve calcification at diagnosis is highly associated with rate of AS progression.3 Despite the huge clinical significance of CAVD, there are currently no pharmacological therapies to improve the outcomes of this disease. Furthermore, statins have proven ineffective in blocking calcification and treating CAVD to date9, 10, 11, leading to the idea that mechanisms beyond those involved in atherosclerosis need to be considered in CAVD.12 Clearly, a better understanding of the etiology and signaling pathways regulating aortic valve calcification is essential for development of therapeutics for preventing and treating this debilitating disease.

Wnt proteins are secreted glycoproteins known for their importance in cardiovascular development, playing key roles in cell type specification, morphogenesis, and cardiac valve formation.13 In recent years, the role of the canonical Wnt signaling pathway (β-catenin dependent) in osteochondrogenic differentiation of tunica media cells in diseased, calcified blood vessels has come to the forefront.14, 15 Upon binding of paracrine Wnt ligands to the transmembrane Frz and LRP5/6 co-receptor complexes of medial cells,16, 17 the cytoplasmic degradation complex of axin, APC and GSK3β is disassembled, allowing β-catenin to enter the nucleus and induce Runx2 and/or LEF1-mediated osteogenic differentiation and calcification.18 Supporting a potential role of canonical Wnts in CAVD, LRP5/Wnt3 was abundantly expressed in calcified human aortic valves.19 On the other hand, non-canonical Wnts act through β-catenin independent signaling pathways, and much less is known about their potential roles in cardiovascular calcification.

In this issue of ATVB, Albanese et al20 have uncovered the potential importance of non-canonical Wnt signaling in CAVD. The authors capitalized on access to extremely well-characterized normal and diseased human valve tissues and cells to perform an impressive array of immunochemistry, western blotting, gene expression studies, and in vitro functional studies. They found that Wnt5a, a dual action non-canonical Wnt that either inhibits Wnt/β-catenin pathway via direct inhibition of LRP6 or activates Wnt-catenin pathway in the presence of Frz4,21 occurred only in or around calcified areas of diseased human aortic valves, while Wnt5b and Wnt11 were more ubiquitously distributed throughout the areas of inflammation, fibrosis, lipid core, and calcification. Importantly, recombinant forms of all three non-canonical Wnts promoted apoptosis, expression of genes associated with osteochondrogenic differentiation, and calcification of human aortic valve interstitial cells. Finally, a positive correlation of non-canonical Wnt 5b and Wnt11 immunoreactivity with aortic valve stenosis parameters, such as aortic jet velocity, Pmax and Pmean, as well as preoperative risk assessment score, were observed.

This study provides strong evidence for the association of non-canonical Wnts with aortic valve calcification and stenosis, and determined for the first time their pro-apoptotic and osteochondrogenic effects on cultured valve cells. Together with previous studies, this work supports the hypothesis that both canonical and non-canonical Wnt signaling pathways may contribute to detrimental calcification processes in CAVD, including apoptosis and osteochondrogenic differentiation. However, none of the studies to date have proven causality of Wnt signaling in CAVD, or which pathways may be most important for valve calcification and subsequent AS. Additional gain and loss of function studies in appropriate animal models are critical to determine which Wnt signaling pathways, if any, may indeed serve as therapeutic targets to block valve calcification, or biomarkers for disease progression.

Acknowledgments

Sources of Funding: This work was supported by grants to CMG from the National Institutes of Health (HL081785, HL62329, HL114611), and the Department of Defense (OR120074).

Footnotes

Disclosures: nothing to disclose

References

  • 1.Iung B, Baron G, Butchart EG, Delahaye F, Gohlke-Barwolf C, Levang OW, Tornos P, Vanoverschelde JL, Vermeer F, Boersma E, Ravaud P, Vahanian A. A prospective survey of patients with valvular heart disease in Europe: The Euro Heart Survey on Valvular Heart Disease. Eur Heart J. 2003;24:1231–1243. doi: 10.1016/s0195-668x(03)00201-x. [DOI] [PubMed] [Google Scholar]
  • 2.Otto CM, Lind BK, Kitzman DW, Gersh BJ, Siscovick DS. Association of aortic-valve sclerosis with cardiovascular mortality and morbidity in the elderly. N Engl J Med. 1999;341:142–147. doi: 10.1056/NEJM199907153410302. [DOI] [PubMed] [Google Scholar]
  • 3.Lindman BR, Clavel MA, Mathieu P, Iung B, Lancellotti P, Otto CM, Pibarot P. Calcific aortic stenosis. Nat Rev Dis Primers. 2016;2:16006. doi: 10.1038/nrdp.2016.6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Stewart BF, Siscovick D, Lind BK, Gardin JM, Gottdiener JS, Smith VE, Kitzman DW, Otto CM. Clinical factors associated with calcific aortic valve disease. Cardiovascular Health Study. J Am Coll Cardiol. 1997;29:630–634. doi: 10.1016/s0735-1097(96)00563-3. [DOI] [PubMed] [Google Scholar]
  • 5.Messika-Zeitoun D, Bielak LF, Peyser PA, Sheedy PF, Turner ST, Nkomo VT, Breen JF, Maalouf J, Scott C, Tajik AJ, Enriquez-Sarano M. Aortic valve calcification: determinants and progression in the population. Arterioscler Thromb Vasc Biol. 2007;27:642–648. doi: 10.1161/01.ATV.0000255952.47980.c2. [DOI] [PubMed] [Google Scholar]
  • 6.Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics–2014 update: a report from the American Heart Association. Circulation. 2014;129:e28–e292. doi: 10.1161/01.cir.0000441139.02102.80. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Nkomo VT, Gardin JM, Skelton TN, Gottdiener JS, Scott CG, Enriquez-Sarano M. Burden of valvular heart diseases: a population-based study. Lancet. 2006;368:1005–1011. doi: 10.1016/S0140-6736(06)69208-8. [DOI] [PubMed] [Google Scholar]
  • 8.Carabello BA. Introduction to aortic stenosis. Circ Res. 2013;113:179–185. doi: 10.1161/CIRCRESAHA.113.300156. [DOI] [PubMed] [Google Scholar]
  • 9.Rossebo AB, Pedersen TR, Boman K, et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med. 2008;359:1343–1356. doi: 10.1056/NEJMoa0804602. [DOI] [PubMed] [Google Scholar]
  • 10.Teo KK, Corsi DJ, Tam JW, Dumesnil JG, Chan KL. Lipid Lowering on Progression of Mild to Moderate Aortic Stenosis: Meta-analysis of the Randomized Placebo-Controlled Clinical Trials on 2344 Patients. Can J Cardiol. 2011;27:800–808. doi: 10.1016/j.cjca.2011.03.012. [DOI] [PubMed] [Google Scholar]
  • 11.van der LD, Yap SC, van Dijk AP, Budts W, Pieper PG, van der Burgh PH, Mulder BJ, Witsenburg M, Cuypers JA, Lindemans J, Takkenberg JJ, Roos-Hesselink JW. Effects of rosuvastatin on progression of stenosis in adult patients with congenital aortic stenosis (PROCAS Trial) Am J Cardiol. 2011;108:265–271. doi: 10.1016/j.amjcard.2011.03.032. [DOI] [PubMed] [Google Scholar]
  • 12.Yutzey KE, Demer LL, Body SC, Huggins GS, Towler DA, Giachelli CM, Hofmann-Bowman MA, Mortlock DP, Rogers MB, Sadeghi MM, Aikawa E. Calcific aortic valve disease: a consensus summary from the Alliance of Investigators on Calcific Aortic Valve Disease. Arterioscler Thromb Vasc Biol. 2014;34:2387–2393. doi: 10.1161/ATVBAHA.114.302523. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Gessert S, Kuhl M. The multiple phases and faces of wnt signaling during cardiac differentiation and development. Circ Res. 2010;107:186–199. doi: 10.1161/CIRCRESAHA.110.221531. [DOI] [PubMed] [Google Scholar]
  • 14.Shao JS, Aly ZA, Lai CF, Cheng SL, Cai J, Huang E, Behrmann A, Towler DA. Vascular Bmp Msx2 Wnt signaling and oxidative stress in arterial calcification. Ann N Y Acad Sci. 2007;1117:40–50. doi: 10.1196/annals.1402.075. [DOI] [PubMed] [Google Scholar]
  • 15.Shao JS, Cheng SL, Pingsterhaus JM, Charlton-Kachigian N, Loewy AP, Towler DA. Msx2 promotes cardiovascular calcification by activating paracrine Wnt signals. J Clin Invest. 2005;115:1210–1220. doi: 10.1172/JCI24140. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Rajamannan NM. The role of Lrp5/6 in cardiac valve disease: LDL-density-pressure theory. J Cell Biochem. 2011;112:2222–2229. doi: 10.1002/jcb.23182. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Cheng SL, Ramachandran B, Behrmann A, Shao JS, Mead M, Smith C, Krchma K, Bello AY, Kovacs A, Kapoor K, Brill LM, Perera R, Williams BO, Towler DA. Vascular smooth muscle LRP6 limits arteriosclerotic calcification in diabetic LDLR−/− mice by restraining noncanonical Wnt signals. Circ Res. 2015;117:142–156. doi: 10.1161/CIRCRESAHA.117.306712. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Hu H, Hilton MJ, Tu X, Yu K, Ornitz DM, Long F. Sequential roles of Hedgehog and Wnt signaling in osteoblast development. Development. 2005;132:49–60. doi: 10.1242/dev.01564. [DOI] [PubMed] [Google Scholar]
  • 19.Caira FC, Stock SR, Gleason TG, McGee EC, Huang J, Bonow RO, Spelsberg TC, McCarthy PM, Rahimtoola SH, Rajamannan NM. Human degenerative valve disease is associated with up-regulation of low-density lipoprotein receptor-related protein 5 receptor-mediated bone formation. Journal of the American College of Cardiology. 2006;47:1707–1712. doi: 10.1016/j.jacc.2006.02.040. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Albanese I, Yu B, Al-Kindi H, Barratt B, Ott L, Al-Refai M, de VB, Shum-Tim D, Cerruti M, Gourgas O, Rheaume E, Tardif JC, Schwertani A. Role of Noncanonical Wnts Signaling Pathway in Human Aortic Valve Calcification. Arterioscler Thromb Vasc Biol. 2016 Dec 8; doi: 10.1161/ATVBAHA.116.308394. epub ahead of print. [DOI] [PubMed] [Google Scholar]
  • 21.Mikels AJ, Nusse R. Purified Wnt5a protein activates or inhibits beta-catenin-TCF signaling depending on receptor context. PLoS Biol. 2006;4:e115. doi: 10.1371/journal.pbio.0040115. [DOI] [PMC free article] [PubMed] [Google Scholar]

RESOURCES